Optimizing panel-based tumor mutational burden (TMB) measurement
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND Panel-based estimates of Tumor Mutational Burden (psTMB) are increasingly replacing whole-exome-sequencing (WES) Tumor mutational burden as predictive biomarker of immune checkpoint blockade (ICB). DESIGN A mathematical law describing psTMB variability was derived using a random mutation model and complemented by the contributions of non-randomly mutated real-world cancer genomes and intratumoral heterogeneity through simulations in publicly available datasets. RESULTS The coefficient of variation (CV) of psTMB decreased inversely proportional with the square root of the panel size and the square root of the TMB level. In silico simulations of all major commercially available panels in the TCGA pan-cancer cohort confirmed the validity of this mathematical law and demonstrated that the CV was 35% for TMB=10 muts/Mbp for the largest panels of size 1.1-1.4 Mbp. Accordingly, misclassification rates (gold standard: WES) to separate "TMBhigh" from "TMBlow" using a cut-point of 199 mutations were 10-12% in TCGA-LUAD and 17-19% in TCGA-LUSC. A novel three-tier psTMB classification scheme which accounts for the likelihood of misclassification is proposed. Analysis of two independent datasets revealed that small gene panels were poor predictors of ICB response. Moreover, we noted significant intratumoral variance of psTMB scores in the TRACERx 100 cohort and identified indel burden in subsets of TMB high cases. CONCLUSIONS A universal mathematical law describes accuracy limitations inherent to psTMB, which result in significant misclassification rates. This scenario can be controlled by two measures: i) a panel design that is based on the mathematical law described herein: halving the CV requires a fourfold increase in panel size, ii) a novel three-tier TMB classification scheme. Moreover, inclusion of indel burden can complement TMB reports. This work has significant implications for panel design, TMB testing, clinical trials and patient management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Due to potentially severe adverse effects [2] and substantial costs it is paramount to prospectively identify patients that most likely benefit from such treatment strategies.”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×
“Currently, PD-L1 expression as assessed by immunohistochemistry is the most widely adopted and approved predictive biomarker for ICB [3] but its predictive power, especially negative predictive value, is limited [4].”
BackgroundGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 1×
“This paradigm is supported by accumulating evidence that tumors with higher TMB are more likely to respond to ICB in various settings including PD-(L)1 blockade in non-small-cell lung cancer (NSCLC) [9] and urothelial carcinoma [10], CTLA-4 blockade in malignant melanoma [11, 12] and combined PD(L)-1 and CTLA-4 blocka…”
MethodRosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 1×
“This paradigm is supported by accumulating evidence that tumors with higher TMB are more likely to respond to ICB in various settings including PD-(L)1 blockade in non-small-cell lung cancer (NSCLC) [9] and urothelial carcinoma [10], CTLA-4 blockade in malignant melanoma [11, 12] and combined PD(L)-1 and CTLA-4 blocka…”
MethodNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 4×
“We analyzed two clinically annotated cohorts of ICB treated patients with tumors characterized by WES [13, 28].”
MethodResultInfluentialClonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
Self-citationGenomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · cited 1×
“This paradigm is supported by accumulating evidence that tumors with higher TMB are more likely to respond to ICB in various settings including PD-(L)1 blockade in non-small-cell lung cancer (NSCLC) [9] and urothelial carcinoma [10], CTLA-4 blockade in malignant melanoma [11, 12] and combined PD(L)-1 and CTLA-4 blocka…”
MethodDevelopment of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683 · cited 2×
“The predictive power of TMB as biomarker for response to ICB is currently investigated in many clinical trials [22, 23] across various cancer types.”
BackgroundMethodSelf-citationFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503 · cited 1×
“The definition of cut-points to separate ‘TMBhigh’ from ‘TMBlow’ tumors is not consistent in recent NSCLC trials: For example, in the CheckMate (CM) trials CM012 [15], CM227 [13] and CM026 [17] cut-points of 158 mutations, 199 mutations (estimated from a panel-based cut-point of 10 mutations per Mbp [20]) and 243 soma…”
ResultSelf-citationTracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349 · cited 2×
“We compared the TMB in different regions of 100 tumors of the TRACERx lung cancer cohort [27].”
BackgroundMethodSelf-citationPan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447 · cited 1×
“It does not only fight virus-driven tumors and limits pro-tumorigenic states of inflammation, but also monitors cells for expression of neoantigens and cell stress induced proteins [1].”
BackgroundRizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095 · cited 1×
“The definition of cut-points to separate ‘TMBhigh’ from ‘TMBlow’ tumors is not consistent in recent NSCLC trials: For example, in the CheckMate (CM) trials CM012 [15], CM227 [13] and CM026 [17] cut-points of 158 mutations, 199 mutations (estimated from a panel-based cut-point of 10 mutations per Mbp [20]) and 243 soma…”
ResultSelf-citationBiological and therapeutic impact of intratumor heterogeneity in cancer evolution
McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077
Self-citationTurajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Al Bakir, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 911 · cited 1×
“[36], our work highlights indel burden as an independent parameter in the mutational spectrum of TMB.”
BackgroundSelf-citationHellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893 · cited 3×
“This paradigm is supported by accumulating evidence that tumors with higher TMB are more likely to respond to ICB in various settings including PD-(L)1 blockade in non-small-cell lung cancer (NSCLC) [9] and urothelial carcinoma [10], CTLA-4 blockade in malignant melanoma [11, 12] and combined PD(L)-1 and CTLA-4 blocka…”
MethodGenomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Miao, D., Margolis, C. A., Vokes, N. I., Liu, D., Taylor-Weiner, A., Wankowicz, S. M., Adeegbe, D., Keliher, D., Schilling, B., Tracy, A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0200-2 · Cited by 620 · cited 4×
“dataset [28], we compared the capability of psTMB to separate responders (CR/PR, n1⁄4 70) from patients with progressive disease (PD, n1⁄4 123).”
MethodInfluentialTumor neoantigens: building a framework for personalized cancer immunotherapy
Gubin, M. M., Artyomov, M. N., Mardis, E. R., & Schreiber, R. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80008 · Cited by 613 · cited 1×
“The more mutations a tumor accumulates, the higher the likelihood of production and subsequent presentation of neoantigens on major histocompatibility complex (MHC) molecules resulting in a higher likelihood of tumor cell cytotoxicity after inhibition of checkpoint signals [8].”
BackgroundMandal, R., Samstein, R. M., Lee, K.-W., Havel, J. J., Wang, H., Krishna, C., Sabio, E. Y., Makarov, V., Kuo, F., Blecua, P., et al. (2019) · Science · doi:10.1126/science.aau0447 · Cited by 557 · cited 1×
“We found that the proportion of indels (in relation to missense mutations) in conjunction with either high or low TMB values identifies different tumor types and genetic subgroups including MSI-H cases which are well known to respond to ICB [37].”
BackgroundTranslational Implications of Tumor Heterogeneity
Jamal-Hanjani, M., Quezada, S. A., Larkin, J., & Swanton, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1429 · Cited by 549
Self-citationProgrammed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
Kerr, K. M., Tsao, M.-S., Nicholson, A. G., Yatabe, Y., Wistuba, I. I., & Hirsch, F. R. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000526 · Cited by 269 · cited 1×
“Currently, PD-L1 expression as assessed by immunohistochemistry is the most widely adopted and approved predictive biomarker for ICB [3] but its predictive power, especially negative predictive value, is limited [4].”
BackgroundStenzinger, A., Allen, J. D., Maas, J., Stewart, M. D., Merino, D. M., Wempe, M. M., & Dietel, M. (2019) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22733 · Cited by 239
Self-citationAllgäuer, M., Budczies, J., Christopoulos, P., Endris, V., Lier, A., Rempel, E., Volckmar, A.-L., Kirchner, M., von Winterfeld, M., Leichsenring, J., et al. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.14 · Cited by 212 · cited 2×
“The predictive power of TMB as biomarker for response to ICB is currently investigated in many clinical trials [22, 23] across various cancer types.”
BackgroundMethodSelf-citationThe impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
Garofalo, A., Sholl, L., Reardon, B., Taylor-Weiner, A., Amin-Mansour, A., Miao, D., Liu, D., Oliver, N., MacConaill, L., Ducar, M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0333-9 · Cited by 179
A grey zone for quantitative diagnostic and screening tests
Coste, J., & Pouchot, J. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg054 · Cited by 161 · cited 1×
“This concept is transparent for clinicians as it conveys which TMB values to take for certain and which might be more error prone, a concept proposed for quantitative diagnostic tests before [32].”
BackgroundSize matters: Dissecting key parameters for panel‐based tumor mutational burden analysis
Buchhalter, I., Rempel, E., Endris, V., Allgäuer, M., Neumann, O., Volckmar, A., Kirchner, M., Leichsenring, J., Lier, A., von Winterfeld, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.31878 · Cited by 154
Self-citationEndris, V., Buchhalter, I., Allgäuer, M., Rempel, E., Lier, A., Volckmar, A., Kirchner, M., von Winterfeld, M., Leichsenring, J., Neumann, O., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32002 · Cited by 105 · cited 1×
“preanalytical factors, enrichment and sequencing technologies [25]), which is beyond the scope of this work.”
BackgroundSelf-citationBudczies, J., Seidel, A., Christopoulos, P., Endris, V., Kloor, M., Győrffy, B., Seliger, B., Schirmacher, P., Stenzinger, A., & Denkert, C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1526613 · Cited by 78 · cited 1×
“For only a few cancer types, including colorectal cancer, stomach cancer and uterine corpus endometrial carcinoma, TMB shows a bi- or multimodal distribution [30].”
BackgroundSelf-citationTCR repertoires of intratumoral T‐cell subsets
Linnemann, C., Mezzadra, R., & Schumacher, T. N. M. (2014) · Immunological Reviews · doi:10.1111/imr.12140 · Cited by 63
Lih, C., & Takebe, N. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.05.003 · Cited by 27 · cited 1×
“Employing two datasets [13, 28], we showed that the AUC of psTMB substantially differs from WES-TMB particularly when using small gene panels [31] leading to substantial clinical misclassifications.”
MethodSzustakowski, J. D., Green, G. A., Geese, W. J., Zerba, K. E., & Chang, H. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-5528 · Cited by 12
Cited by
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Sha, D., Jin, Z., Budczies, J., Kluck, K., Stenzinger, A., & Sinicrope, F. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0522 · Cited by 859
Self-citationTumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
Strickler, J. H., Hanks, B. A., & Khasraw, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3054 · Cited by 418
Metadata
- Authors
- Budczies, J., Allgäuer, M., Litchfield, K., Rempel, E., Christopoulos, P., Kazdal, D., Endris, V., Thomas, M., Fröhling, S., Peters, S., Swanton, C., Schirmacher, P., & Stenzinger, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 30
- Issue
- 9
- Pages
- 1496-1506
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2956015063
- Cited by
- 159
- References
- 36
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.